In NSCLCs, tumor infiltrating CD8+ T-cells or CD4+ that simultaneously express CD39 are characterized by a strong anti-tumor reactivity and have a high probability to react with neo-antigens of the tumor [47]. The gene discussed is ENTPD1; the disease is neoplasm.